An observational study in Pulmonary Hypertension and Pulmonary Hypertension Crisis, sponsored by Peking Union Medical College Hospital. Recruiting at 4 sites in China. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Peking Union Medical College Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Hypertension, Pulmonary with a site in China — 31 open to participants now, 36 under way, 5 of them phase 3. Hypertension, Pulmonary · China.
Among the 85 studies in Hypertension, Pulmonary with a site in China, this one is the 4th largest by planned enrollment of the 36 observational ones that give a count, is one of 5 that started in 2026, is one of 36 observational ones, reaches primary completion later than 31 of the 35 other live ones, and was the 82nd registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →31 of the 85 studies in Hypertension, Pulmonary with a site in China are open now. Recruiting first, the newest first:
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Xiamen Cardiovascular Hospital, Xiamen University · Sites in China
Ages 18–80
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+
Beijing Continent Pharmaceutical Co, Ltd. · Sites in China
Ages 18–45 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 21 · Phase 4 2
First in 2004; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 110 across 380 observational studies indexed under Hypertension, Pulmonary.
Median enrollment 100 across the 47 interventional studies, 750 across the 36 observational. Of the 38 that completed or were terminated, 14 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 85 have an industry lead sponsor. The 10 most frequent:
Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Peking Union Medical College Hospital has 1 study filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
5 of the studies in Hypertension, Pulmonary with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT07292896First Hospital of China Medical UniversityA Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography | 2026-12 |
| NCT06023134Jingyi RenClinical Characteristics and Outcomes of Patients With Pulmonary Hypertension Associated Right Heart Failure | 2027-09-01 |
| NCT06980584Beijing Chao Yang HospitalStudy on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 85 studies in Hypertension, Pulmonary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about pulmonary hypertension crisis (PHC) - a severe, and often fatal complication - in patients with pulmonary hypertension (PH). The main questions this study aims to answer are:
What are the clinical and hemodynamic features of PHC, and what underlying pathophysiological mechanisms cause it to develop? Can these features be used to diagnostic PHC, predict who is at risk of developing it or dying from it, and develop targeted prevention and treatment of PHC?
A multi-center registry platform and biobank will be established to enroll and follow up patients with PH. Clinical data, hemodynamic measurements, and biological specimen will be collected. Risk prediction and early warning tools of PHC will be developed.
Pulmonary hypertension crisis (PHC) is a severe and fatal complication of pulmonary hypertension (PH), characterized by the sudden elevation of pulmonary vascular resistance, acute right hear failure and collapse of systemic circulation. However, PHC currently lacks any internationally accepted definition or diagnostic criteria, and it is still unclear which are the clinical, pathophysiological and molecular risk factors of PHC.
This study aims to establish a large clinical cohort of patients with PH, validate the definition of PHC, identify risk factors of PHC occurrence and mortality, and develop tools for the risk-prediction and early-warning of PHC.
This is a multi-center, prospective cohort study with a retrospective component for model training. Following national health-information standards, a standardized registry dataset will be established to cover demographics, clinical features, laboratory tests, imaging, and hemodynamic profile. Existing PH cohort databases will be integrated and expanded to a target of 5,000 patients. A subset of cases with right heart catheter parameters (RHC) will be extracted. A multi-center biospecimen management platform will be established.
For PHC onset, the investigators will assemble a clinical-molecular-imaging feature set and use convolutional neural networks and tree-based algorithms for feature extraction, then build a cross-modal prediction model using multi-task learning, neural networks, and a Transformer architecture. The model will be prospectively validated and tuned against real-world performance. For PHC mortality, models will be built on patients meeting the new PHC criteria, using 28-day attributable death, all-cause death, and long-term death as endpoints. Models will be trained on a retrospective cohort and then evaluated for accuracy and generalizability on both an internal validation set and an external prospective-cohort validation set.
Patients with pulmonary hypertension confirmed by right heart catheterization
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with right heart catheter confirmed pulmonary hypertension
Pulmonary hypertension crisis
Critical increase of pulmonary vascular resistance accompanied by right heart dysfunction and systemic hypoperfusion
Time frame: From enrollment to 3 years after enrollment
28 day mortality attributed to pulmonary hypertension crisis
Death attributed to pulmonary hypertension crisis within 28 days of hospitalization
Time frame: From hospitalization to 28 days
All cause mortality within hospitalization
All cause death within hospitalization
Time frame: From hospitalization to discharge or documented death, whichever is earlier, assessed up to 3 years
All cause mortality within 3 years
All cause death within 3 years from the diagnosis of pulmonary hypertension crisis
Time frame: From the diagnosis of pulmonary hypertension crisis to documented death, assessed up to 3 years
Plan to share: Yes — IPD that underlie the results reported in our publications will be shared after de-identification, including clinical, hemodynamic, laboratory, and imaging data (tables, figures, and appendices).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning 1 year after publication with no end date
Access criteria: Researchers who submit a methodologically sound proposal will be able to access the de-identified individual participant data and supporting documents. Proposals should be directed to the principal investigator at pjm731@hotmail.com. To gain access, requestors will be required to sign a data access agreement, and data will be shared for the purpose of achieving the aims in the approved proposal.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.
Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 36 months is below that.
Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking Union Medical College Hospital →